The RUTH study, performed in postmenopausal women at high risk of

The RUTH study, performed in postmenopausal women at high risk of cardiovascular disease [164], showed that raloxifene had no effect on cardiovascular

death and on the incidence of PHA-848125 in vivo coronary heart disease and stroke [165]. The efficacy of raloxifene has been shown in women with osteopenia [166] and is not dependent on the level of fracture risk assessed by FRAX [167]. In summary, the overall risk benefit ratio of raloxifene is favourable, and the drug is approved widely for the prevention and treatment of postmenopausal osteoporosis. Bazedoxifene is a selective oestrogen receptor modulator that has been approved in Europe but is only available in Spain and Germany. In phase 3 clinical trials, bazedoxifene was shown to significantly reduce the risk of new vertebral fracture, Protein Tyrosine Kinase inhibitor with favourable effects on bone mineral density, bone turnover markers and the lipid profile [168, 169]. In a subgroup of women at increased risk of fracture, bazedoxifene significantly decreased non-vertebral fracture risk. In contrast to raloxifene, the efficacy of bazedoxifene is dependent

on the level of fracture risk assessed by FRAX [170]. In common with raloxifene, venous thromboembolic events, primarily deep vein thromboses, leg cramps and hot flushes were more frequently reported in the active treatment groups compared with the placebo group [171]. Bisphosphonates Bisphosphonates are stable analogues of pyrophosphate characterised by a P–C–P bond. A variety of Loperamide bisphosphonates has been synthesized, the potency of which depends on the length and structure of the side chain. Bisphosphonates have a strong affinity for bone apatite, both in vitro and in vivo, which is the basis for their clinical use. They are potent inhibitors of bone resorption and produce their effect by reducing the recruitment and activity of

osteoclasts and increasing their apoptosis. The potency and chemical affinity to bone of bisphosphonates determines their effect to inhibit bone resorption and varies greatly from compound to compound. Potency differences can range 10,000-fold in vitro, so that the doses used clinically also vary. The mechanism of action on osteoclasts includes inhibition of the proton vacuolar adenosine triphosphatase (ATPase) and alteration of the cytoskeleton and the ruffled border. Aminobisphosphonates also inhibit the farnesyl pyrophosphate synthase step in the mevalonate pathway, thereby modifying the isoprenylation of guanosine triphosphate binding proteins. Oral bioavailability of bisphosphonates is low, around 1 % of the dose ingested, and is impaired by food, calcium, iron, coffee, tea and orange juice. Bisphosphonates are quickly High Content Screening cleared from plasma, about 50 % being deposited in bone and the remainder excreted in urine. Their half-life in bone is very prolonged [172].

Comments are closed.